Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas

Cancer Letters

Volumn 186, Issue 1, 2002, Pages 59-65

  Nagai, Hisaki ^a   Kim, Yong Sung ^b   Konishi, Noboru ^b   Baba, Masaru ^b   Kubota, Takeo ^a   Yoshimura, Akihiko ^b   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Hepatocellular carcinoma (HCC); Methylation; SSI 1 SOCS 1 JAB

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN JAB; PROTEIN SSI 1; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CHROMOSOME LOSS; CONTROLLED STUDY; CPG ISLAND; EXON; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANS-ACTIVATORS;

EID: 0036883618     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00244-6     Document Type: Article

References (22)

1. Koshy R., Caselmann W.H. Oncogenes, Tumor Suppressors and Co-Factors in Hepatocellular Carcinoma. Hepatitis B Virus-Molecular Mechanisms in Disease and Novel Strategies for Therapy. 1998;182-218 Imperial College Press, London.
2. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
3. Matsubara K. Chromosomal Changes Associated with Hepatitis B Virus DNA Integration and Hepatocarcinogenesis. Molecular Biology of the Hepatitis B Virus. 1991;245-261 CRC Press Inc, Boca Raton, FL. (Chapter 13).
4. Laird P.W., Jaenish R. DNA methylation and cancer. Hum. Mol. Genet. 3:1994;1487-1495.
5. Nagai H., Ponglikitmongkol M., Mita E., Ohmachi Y., Yoshikawa H., Saeki R., Yumoto Y., Nakanishi T., Matsubara K. Aberration of genomic DNA in association with human hepatocellular carcinomas detected by 2-D gel analysis. Cancer Res. 54:1994;1545-1550.
6. Nagai H., Kim Y.S., Lee K.T., Chu M.Y., Konishi N., Fujimoto J., Baba M., Matsubara K., Emi M. Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis. J. Hepatol. 34:(3):2001;416-421.
7. Starr R., Wilson T.A., Viney E.M., Murray L.J.L., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nocola N.A., Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature (Lond.). 387:1997;917-920.
8. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kaanakura Y., Komiya S., Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature (Lond.). 387:1997;921-924.
9. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., Akira S., Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature (Lond.). 387:1997;924-927.
10. Hirayama T., Yamaki E., Hata A., Tsuji M., Hashimoto K., Yamamoto M., Emi M. Five familial hypercholesterolemic kindreds in Japan with novel mutations of the LDL receptor gene. J. Hum. Genet. 43:(4):1998;250-254.
11. Kitamura Y., Minobe K., Nakata T., Shimizu K., Tanaka S., Fujimori M., Yokoyama S., Ito K., Onda M., Emi M. Ret/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J. Hum. Genet. 44:(2):1999;96-102.
12. Koyama M., Nagai H., Bando K., Ito M., Moriyama Y., Emi M. Localization of a target region of allelic loss to a 1-cM interval on chromosome 16p13.13 in hepatocellular carcinoma. Jpn. J. Cancer Res. 90:(9):1999;951-956.
13. Bando K., Nagai H., Matsumoto S., Koyama M., Kawamura N., Onda M., Emi M. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosome Cancer. 25:1999;284-289.
14. Tsukamoto K., Haruta K., Shiba T., Emi M. Isolation and mapping of a polymorphic CA repeat sequence at the human interleukin 6 locus. J. Hum. Genet. 43:(1):1998;71-72.
15. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
16. Sato M., Mori Y., Sakurada A., Fujiwara S., Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum. Genet. 103:1998;96-101.
17. Kanai Y., Ushijima S., Tsuda H., Sakamoto M., Sugimura T., Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn. J. Cancer Res. 87:1996;1210-1217.
18. Wen Z., Zhong Z., Darnell J.E. Jr. Maximal activation of transcription by Stat1 and Stat3 require both tyrosine and serine phosphorylation. Cell. 82:1995;241-250.
19. Ichiba M., Nakajima K., Yamanaka Y., Kiuchi N., Hirano T. Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J. Biol. Chem. 273:1998;6132-6138.
20. Narazaki M., Fujimoto M., Matsumoto T., Morita Y., Saito H., Kajita T., Yoshizaki K., Naka T., Kishimoto T. Proc. Natl. Acad. Sci. USA. 95:1998;13130-13134.
21. Garcia R., Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5:(2):1998;79-85.
22. Turkson J., Bowman T., Adnane J., Zhang Y., Djeu J.Y., Sekharam M., Frank D.A., Holzman L.B., Wu J., Sebti S., Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell Biol. 19:(11):1999;7519-7528.